Home / Health / FDA Declines Sobi's Gout Therapy Approval
FDA Declines Sobi's Gout Therapy Approval
27 Jun
Summary
- FDA declined Sobi's therapy for uncontrolled gout.
- FDA cited manufacturing control issues, not safety.
- Sobi will meet FDA to discuss resubmission plans.
The U.S. Food and Drug Administration has declined to approve Swedish drugmaker Sobi's therapy intended for patients with uncontrolled gout. This decision was communicated to Sobi via a complete response letter. The FDA's request for additional data focused on manufacturing controls and issues at contract manufacturing facilities. Crucially, the agency did not raise any concerns regarding the therapy's safety or efficacy.
Sobi, based in Stockholm, has stated its intention to request a meeting with the FDA. The purpose of this meeting will be to discuss the process for resubmitting the therapy application. Sobi will also collaborate with its contract manufacturing organizations to rectify the identified deficiencies. Uncontrolled gout is a severe form of inflammatory arthritis characterized by persistently high uric acid levels and persistent symptoms despite treatment.
